<DOC>
	<DOC>NCT01693861</DOC>
	<brief_summary>Observational, non randomized study aimed at measuring the effect of chemotherapy in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>"Cancersensor" Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologicallyconfirmed metastatic colorectal cancer; 0 to 3 prior chemotherapy lines; Signed informed consent; Good understanding of the protocol and of the followup; Estimated life expectancy exceeding 3 months; At least one measurable metastatic lesion (RECIST criteria); Performance Status (WHO) of 0 to 2; Good haematological, hepatic and renal functions. More than 2 surgical resections of metastases from colorectal cancer; Poor performance status (&gt;2); Poor haematological, hepatic or renal functions; Uncontrolled chronic disease; Serious unhealed wound, ulcer or fracture within the previous month; Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion; Pregnancy or breastfeeding during the previous month; Transmeridian trip of more than 4 time zones within the prior 2 weeks; Person with legal restriction to participate into clinical research, according to the current law in France.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Chronotherapy</keyword>
	<keyword>Urine</keyword>
	<keyword>Nucleosides</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Treated with chemotherapy</keyword>
</DOC>